🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Nephrocare Health Services Limited NEPHROPLUS NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.nephroplus.com
Company Profile ↓
₹608.90
+29.21% 1Y
Mkt Cap₹6,123.04 Cr
P/E71.80
P/B5.54
52W High₹765.35
52W Low₹449.15
Book Value₹111.27
EPS (TTM)₹8.48

Company Overview

Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 250.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 33.9% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.07.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹994.47 Cr (+32.9% YoY); net profit ₹76.84 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +23.7%, earnings +15.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 33.9%, profit CAGR 250.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:33.87%
1 Year:23.70%

Compounded Profit Growth

5 Years:250.60%
1 Year:15.20%

Stock Price Performance

1 Year:+29.21%
6 Months:+14.12%
3 Months:-10.18%
1 Month:-18.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 51% of range
₹449.15 ₹765.35
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)27.25 · Oversold
Price Performance
1M-18.99%
3M-10.18%
6M+14.12%
1Y+29.21%
Valuation vs Sector

P/E of 71.80 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 33.9% over 5 years.
  • Profit CAGR of 250.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 71.8.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
71.80
Industry PE
36.43
Forward P/E
28.81
PEG Ratio
-
Book Value
₹111.27
Price to Book
5.54
P/S
5.89
EV/EBITDA
25.97
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
33.87%
Profit 5Y
250.60%
Revenue (YoY)
23.70%
Earnings (YoY)
15.20%

Profitability & Returns

ROCE
13.27%
ROE
6.88%
ROA
5.22%
Profit Margin
8.08%
Op Margin
13.96%
Gross Margin
38.77%
EPS (Latest Qtr)
₹2.96
EPS (TTM)
₹8.48

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
2.69
Current Ratio
2.80
Debt
₹79.71 Cr
Total Assets
₹1,470.87 Cr
Current Assets
₹839.17 Cr
Working Capital
₹539.76 Cr

Ownership

Promoter Holding
49.30%
Chg in Prom Hold
-5.30%
FII / Inst Holding
38.49%
Chg in FII Hold
1.50%

Financial Snapshot

Enterprise Value
₹6,123.04 Cr
Total Revenue (TTM)
₹1,052.82 Cr
EBITDA
₹228.93 Cr
Free Cash Flow
₹113.22 Cr
Operating Cash Flow
₹232.58 Cr
Shares Outstanding
₹10.06 Cr
Gross Margin
38.77%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NEPHROPLUS Nephrocare Health Services Limited NSEPHARMA 608.90 71.80 ₹6,123.04 Cr 0.00% 13.27% 6.88% 33.87% 250.60%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue 197.26 Cr219.19 Cr246.00 Cr259.73 Cr265.62 Cr
Cost of Revenue 87.40 Cr95.90 Cr-109.19 Cr110.16 Cr
Gross Profit 109.86 Cr123.29 Cr-150.54 Cr155.46 Cr
Operating Expenses 83.94 Cr91.36 Cr182.00 Cr111.53 Cr127.53 Cr
Operating Income 25.92 Cr31.93 Cr41.00 Cr39.00 Cr27.92 Cr
EBITDA 49.46 Cr55.41 Cr64.00 Cr64.18 Cr62.24 Cr
Interest Expense 4.85 Cr6.12 Cr45.00 Cr5.96 Cr3.18 Cr
Pretax Income 26.43 Cr29.92 Cr-1.00 Cr36.36 Cr33.22 Cr
Tax Provision 6.33 Cr5.05 Cr-14.27 Cr4.12 Cr2.85 Cr
Net Income 20.11 Cr24.87 Cr-9.00 Cr32.24 Cr30.37 Cr
Diluted EPS 2.002.48-5.243.352.96

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 286.00 Cr-414.52 Cr539.55 Cr748.34 Cr994.47 Cr
Cost of Revenue --221.41 Cr283.86 Cr352.24 Cr418.93 Cr
Gross Profit --193.11 Cr255.69 Cr396.11 Cr575.53 Cr
Operating Expenses 248.00 Cr-189.47 Cr202.22 Cr297.12 Cr436.59 Cr
Operating Income 3.00 Cr-3.64 Cr53.47 Cr98.98 Cr138.95 Cr
EBITDA 37.00 Cr-52.87 Cr107.05 Cr178.77 Cr244.93 Cr
Interest Expense 7.00 Cr-14.59 Cr19.00 Cr18.87 Cr57.97 Cr
Pretax Income 1.00 Cr--8.59 Cr33.16 Cr87.44 Cr97.47 Cr
Tax Provision 31.00 L-3.20 Cr-1.97 Cr20.34 Cr20.63 Cr
Net Income 1.00 Cr--11.79 Cr35.13 Cr67.10 Cr76.84 Cr
Diluted EPS 3.40--1.173.506.698.10

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 428.00 Cr-666.23 Cr806.02 Cr996.46 Cr1,470.87 Cr
Current Assets --324.25 Cr390.03 Cr545.36 Cr839.17 Cr
Cash & Equivalents --13.19 Cr61.15 Cr125.82 Cr123.89 Cr
Inventory --26.27 Cr25.91 Cr26.62 Cr33.04 Cr
Receivables --158.50 Cr202.67 Cr266.42 Cr316.89 Cr
Total Liabilities --277.60 Cr392.31 Cr412.35 Cr354.37 Cr
Current Liabilities --174.61 Cr242.59 Cr283.89 Cr299.41 Cr
Long Term Debt --81.48 Cr123.24 Cr96.00 Cr4.70 L
Total Debt 140.00 Cr-213.73 Cr267.84 Cr257.78 Cr79.71 Cr
Total Equity 247.00 Cr-388.63 Cr413.71 Cr584.11 Cr1,116.49 Cr
Shares Outstanding --10.03 Cr10.03 Cr10.03 Cr10.03 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 32.00 Cr-11.27 Cr72.28 Cr135.35 Cr232.58 Cr
Investing Cash Flow -62.00 Cr--78.21 Cr-50.66 Cr-125.07 Cr-410.44 Cr
Financing Cash Flow 36.00 Cr-59.97 Cr26.74 Cr54.37 Cr157.11 Cr
Capital Expenditure -61.00 Cr--73.74 Cr-80.00 Cr-100.80 Cr-119.36 Cr
Free Cash Flow -29.00 Cr--62.47 Cr-7.72 Cr34.55 Cr113.22 Cr
Net Change in Cash 5.00 Cr--6.97 Cr48.36 Cr64.64 Cr-20.75 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --46.6%47.4%52.9%57.9%
Operating Margin % 1.0%-0.9%9.9%13.2%14.0%
Net Margin % 0.3%--2.8%6.5%9.0%7.7%
ROE % 0.4%--3.0%8.5%11.5%6.9%
ROCE % --0.7%9.5%13.9%11.9%

Shareholding Pattern

Insiders
49.30%
Institutions
38.49%
Public Float
75.93%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEPHROPLUS

Google News Sun, 17 May 2026

NEPHROPLUS Stock Price and Chart — NSE:NEPHROPLUS - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBBa3cxeXJOY1QtbVIxUWpRYjA5R1dzYVVPeDdVWXQycEQ5N1ZGOVNaajBxbjZKUUVXaU83M21WZ1hyQktiLTh6ajltT0tXOHNZbWxldzVNMWRKZ0lzYVBlcA?oc=5" target="_blank">NEPHROPLUS Stock Price and Chart — NS…

Google News Wed, 23 Sep 2026

Nephroplus Block Deal: Investcorp, Bessemer, Promoters Likely To Offload Stake In Up To Rs 650-Crore Sale - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPTjhSYXVjTzByMHFfYmpGdENVSmJzZS1meTdoQ2M4OElFa1VvNTFZQ1JqdUhLTEdpRnVJQW1sWHp2ck1HWlQ3Y3FBaVRIVUFPUnloWGtJVG1qbEhtd0NZeHJZUnpfYUhveTVONzl1Y0EteU9LVTNQWFVGQ1hXdExzZzh4TDd3dEtjVnpwdn…

Google News hu, 18 Dec 2025

Nephrocare Health Services Limited (NEPHROPLUS.NS) stock price, news, quote and history - Yahoo Finance Singapore

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1kbDlCa1JBVmgxd0JSTUltcHM1NlFTZFBXYTlKc3J1a1NTcGhuSUh6ZFA4YzVYTU9ud3FsUklUWFk1YzJfVVpscUlxSHc1UGJIb0cyRUhqbEdKejJpdUE?oc=5" target="_blank">Nephrocare Health Services Limited (NEPH…

Google News Fri, 09 Oct 2026

Nephrocare Health Services (NSEI:NEPHROPLUS) Stock Forecast & Analyst Predictions - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQV1dnSUwydGo3Y281aHBLQXdWZTY1MnNwUXpBTWhOdlBuOHVyQXI5SlEtcVVrVFpXR3FpZ1daVl9sRWJqWWNVRFhRMi1JVjZQUng4RWlndmNXMU5WNV9zeE9EblIyUWJIeGYxLXl2Q3publV3eDJXLVJrN3RsMUliZmI0XzU1cjVHQ1l2cl…

Google News hu, 24 Sep 2026

NEPHROPLUS Share Price Falls 5.13%: Price Action View - Univest

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOTVBvWjFqTDFMWHUxSldCZzlvLXYwNlVjMWNMT3VjSG52NEQ1Q3Nlb3V0Tm00ZjlON3N4eDRVR3diZ0JhMHJlWko5U2hJNDJxeHlZX1lwcDh6R0UxMlFnM3JTbm9pRHcwV2dhaDFKZUNtdlg4VkVlQWhIU0YteHQxRUJTZ0E3WWxmeFhVai…

Google News hu, 13 Aug 2026

NephroPlus off to strong FY27 start as overseas business drives growth: Nomura - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPck5zbl9Ia3RJakRkUlhWMzJWSDJ3QnVNeVZpR1hPSXhOY3hLSjBoV0xMRS1xNDlmbFVZalYtU1pwd0NuTGN2ZlNtVzdMQ2M1OUt1YXdaTzd1ZGtKXzctVVEwcDhISDU2aHc1NmI0ajQ2MHNOZmVxYUZOeFA2TmVNY2hFTVg1QUlfVk5Ian…

NEPHROPLUS — Frequently Asked Questions

What is the current share price of Nephrocare Health Services Limited (NEPHROPLUS)?

As of 2026-10-23 04:58 IST, Nephrocare Health Services Limited (NEPHROPLUS) trades at ₹608.90 on NSE. Its 52-week range is ₹449.15 to ₹765.35.

What is the market capitalisation of NEPHROPLUS?

Nephrocare Health Services Limited (NEPHROPLUS) has a market capitalisation of ₹6,123.04 Cr on NSE.

What is the P/E ratio of NEPHROPLUS?

NEPHROPLUS trades at a trailing price-to-earnings (P/E) ratio of 71.80. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 5.54.

What is the return on equity (ROE) of NEPHROPLUS?

NEPHROPLUS has a return on equity (ROE) of 6.88%. Its return on capital employed (ROCE) is 13.27%.

Is NEPHROPLUS a good stock to buy?

This page provides a data-driven analysis of Nephrocare Health Services Limited (NEPHROPLUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space